

MATERIALS LICENSE

Amendment No. 05

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with application dated July 15, 1985	
1. St. Luke's Episcopal Hospital Calle Guadalupe Final		3. License number	52-16061-01 is amended in its entirety to read as follows:
2. Ponce, Puerto Rico 00731		4. Expiration date	September 30, 1990
		5. Docket or Reference No.	030-10302
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radio-pharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.	
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.	
C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	C. Any	C. 1 millicurie of each byproduct material authorized in Subitem 6.C.	
D. Iodine 131	D. Iodide	D. 300 millicuries	

9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

8510230030 850917
REG2 LIC30
52-16061-01 PDR

111 ML20

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

52-16061-01

Docket or Reference number

030-10302

Amendment No. 05

9. Authorized use (cont)

C. In-vitro studies.

D. For treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma.

CONDITIONS

10. Licensed material shall be used only at the St. Luke's Episcopal Hospital, Guadalupe Street, Ponce, Puerto Rico.
11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."
12. Licensed material listed in item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Julio A. Morales, M.D.

Group I, II, and III

Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
In vitro studies

Luis M. Lopez de Victoria, M.D.

Groups I, II, and III

Iodine 131 as iodide for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
In vitro studies

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.
15. For a period not to exceed sixty (60) days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
- A. Has the prior written permission of the hospital's Administrator and its Medical Isotopes Committee, and
 - B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number:

52-16061-01

Docket or Reference number:

030-10302

Amendment No. 05

(cont'd)

CONDITIONS

15. C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in subitem (a) above and of the license(s) specified in subitems (b) and (c) above. These records shall be maintained for five (5) years from the time the licensee grants its permission under subitem (a) above.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in letters dated July 9, 1980, January 28, 1981, and February 19, 1985; and application dated July 15, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

PAUL R. GUINN

Date SEP 17 1985By Paul R. Guinn

Region II, Nuclear Materials

Safety Section

101 Marietta Street, Suite 2900

Atlanta, GA 30323